Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

被引：0
|
作者：
Nadal, R. [1 ]
Mortazavi, A. [2 ]
Stein, M. [3 ]
Pal, S. K. [4 ]
Davarpanah, N. [1 ]
Parnes, H. L. [1 ]
Ning, Y. M. [1 ]
Cordes, L. M. [1 ]
Lin, J. [1 ]
Bagheri, M. [5 ]
Linderberg, L. [1 ]
Berniger, M. [1 ]
Steinberg, S. M. [6 ]
Moore, T. [4 ]
Lancaster, T. [2 ]
Aviles, M. [3 ]
Costello, R. [1 ]
Bottaro, D. P. [1 ]
Dahut, W. L. [1 ]
Apolo, A. B. [1 ]
机构：
[1] NCI, Med Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Ohio State Univ, Internal Med, James Canc Hosp, Columbus, OH 43210 USA
[3] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[4] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA
[5] NCI, Ctr Canc Res, Radiol & Imaging Sci, Bethesda, MD 20892 USA
[6] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
    McGregor, B. A.
    Paul, M.
    Xie, W.
    Xu, W.
    Bilen, M. A.
    Braun, D. A.
    Berg, S.
    Zhang, T.
    McKay, R. R.
    McDermott, D. F.
    Hammers, H.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1020 - S1020
  • [22] Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
    McGregor, Bradley Alexander
    Huang, Jiaming
    Xie, Wanling
    Xu, Wenxin
    Bilen, Mehmet Asim
    Braun, David A.
    Zhang, Tian
    McKay, Rana R.
    McDermott, David F.
    Hammers, Hans J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
    Grimm, M-O.
    Schostak, M.
    Gruen, C. B.
    Loidl, W. C.
    Pichler, M.
    Zimmermann, U.
    Schmitz-Draeger, B. J.
    Steiner, T.
    Roghmann, F.
    Niegisch, G.
    Schmitz, M.
    Baretton, G.
    Leucht, K.
    Schumacher, U.
    Foller, S.
    Zengerling, F.
    Meran, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1207 - S1208
  • [26] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony B.
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Baccan, Carlos
    Dela Cruz, Christine Marie
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
    Leong, Sally
    Ali, Sana
    Zengin, Zeynep Busra
    Meza, Luis A.
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Govindarajan, Ameish
    Castro, Daniela V.
    Li, Xiaochen
    Kim, Tane
    Melamed, Sam
    Pal, Sumanta Monty
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Efficacy and safety of nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
    Naumann, R. W.
    Oaknin, A.
    Meyer, T.
    Lopez-Picazo, J. M.
    Lao, C.
    Bang, Y-J.
    Boni, V.
    Sharfman, W. H.
    Park, J. C.
    Devriese, L. A.
    Harano, K.
    Chung, C. H.
    Topalian, S. L.
    Zaki, K.
    Chen, T.
    Gu, J.
    Li, B.
    Barrows, A.
    Horvath, A.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 898 - +
  • [29] A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (IaBCC) or metastatic basal cell carcinoma (mBCC).
    Stein, Julie E.
    Brothers, Patricia
    Applebaum, Katie
    Gaskin, Angela
    Wang, Hao
    Taube, Janis M.
    Lipson, Evan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Algazi, Alain Patrick
    Hamid, Omid
    Hodi, F. Stephen
    Moschos, Stergios J.
    Khushalani, Nikhil I.
    Gonzalez, Rene
    Lao, Christopher D.
    Postow, Michael Andrew
    Atkins, Michael B.
    Ernstoff, Marc S.
    Puzanov, Igor
    Kudchadkar, Ragini Reiney
    Thomas, Reena Parada
    Tarhini, Ahmad A.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345